FLGT — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-01

• On March 17, 2026 and as further described in Note 15, Business Combinations, to the condensed consolidated financial statements included in this report, we completed the acquisition of certain assets of Bako Diagnostics and acquired StrataDx, or collectively, the Bako Acquisition, which together pr…

• Our business and prospects are exposed to numerous risks and uncertainties, as described below and in our 2025 Annual Report. In particular, the Bako Acquisition is a major transaction involving the integration of significant operations into our existing laboratory business. As described in greater …

• affected by a number of other factors. See the description of some of the material factors affecting our performance in “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of the 2025 Annual Report.

• The decrease in precision diagnostics revenue was driven by the decline in revenue from our largest customer as this customer begins to perform tests internally. As previously disclosed in our Form 10-K, we expect revenues for our largest customer to continue to decline in 2026 as this customer incr…

• Our customer base includes insurance, institutional, and individual payors. In some periods, our revenue is concentrated on a smaller number of customers. For the laboratory services segment, aggregating customers that are under common control, our largest customer comprised $10.4 million, or 15%, o…

Text removed vs the prior filing · source: 10-Q · 2025-11-07

• Our business and prospects are exposed to numerous risks and uncertainties, as described below and in the 2024 Annual Report. For more information, see “Item 1A. Risk Factors” in Part I of the 2024 Annual Report and “Item 1A. Risk Factors” in Part II of our Quarterly Report for the quarter ended Mar…

• continued development of our therapeutic candidates often requires interaction with the FDA. Depending on the ultimate length or extent of any “government shutdown”, our research and development efforts may also be delayed.

• Revenue increased by $32.1 million, or 16%, from $207.3 million in the nine months ended September 30, 2024, to $239.3 million in the nine months ended September 30, 2025. The increase in revenue between periods was driven by increases of $18.0 million in precision diagnostics, $8.6 million in anato…

• The increase in precision diagnostics revenue was driven by growth in our reproductive health services and continued strength in legacy diagnostic offerings. Anatomic pathology services revenue increased primarily due to the absence of weather-related disruptions and client losses that had affected …

• Our customer base includes insurance, institutional, and individual payors. In some periods, our revenue is concentrated in a smaller number of customers. For the laboratory services segment, aggregating customers that are under common control, one customer comprised $19.2 million, or 23%, of our re…

Text added vs the prior filing · source: 10-Q · 2026-05-01

• During the three months ended March 31, 2026, none of our directors or officers, as each term is defined in Rule 16a-1(f) of the Exchange Act, adopted or terminated “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K, exce…

• On March 4, 2026, Hanlin Gao, our Chief Scientific Officer and Laboratory Director, terminated a Rule 10b5-1 sales plan, intended to satisfy the affirmative defense requirements of Rule 10b5-1(c) of the Exchange Act, originally adopted on November 25, 2025, for the sale of up to 100,000 shares of ou…

• Additionally and on March 9 2026, The Ming Hsieh Trust, or the Hsieh Trust, terminated a prepaid variable forward agreement, dated as of August 21, 2023, with an unaffiliated bank, or the Prepaid Agreement, which constituted a “non‑Rule 10b5‑1 trading arrangement” as defined in Item 408 of Regulatio…

• to terminate the arrangement. Upon the payment of $10.7 million by the Hsieh Trust to the unaffiliated bank, the Pledged Shares were no longer subject to the Prepaid Agreement.

Text removed vs the prior filing · source: 10-Q · 2025-11-07

• During the three months ended September 30, 2025, none of our directors or officers adopted or terminated “Rule 10b5-1 trading arrangement” as defined in Item 408 of Regulation S-K.